SCHEMBL5070033

SCHEMBL5070033

CCCCN(Cc1ccc(O)c(OC)c1)Cc1c(-c2ccc(F)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.37
CASR P41180 1/20 0.36
ABCB1 P08183 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
DRD2 P14416 2/20 0.35
DRD1 P21728 2/20 0.35
DRD4 P21917 2/20 0.35
HTR2C P28335 2/20 0.35
DRD3 P35462 2/20 0.35
NOX1 Q9Y5S8 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CRHR1 P34998 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648771 0.95 C5AR1 (0.45) C5AR1KDM4EGAASIRT2NOX1
SCHEMBL5137337 0.94 C5AR1 (0.41) C5AR1KDM4EGAACASRABCB1
SCHEMBL5136707 0.93 MAPT (0.42) C5AR1DRD2DRD1DRD4DRD3
SCHEMBL5136877 0.93 C5AR1 (0.43) C5AR1GAACASRABCB1RXFP1
SCHEMBL5136086 0.90 C5AR1 (0.41) C5AR1KDM4EGAASIRT2CASR
SCHEMBL5134693 0.90 C5AR1 (0.45) C5AR1KDM4ECRHR1
SCHEMBL652183 0.89 C5AR1 (0.45) C5AR1KDM4EGAASIRT2NOX1
SCHEMBL652664 0.88 C5AR1 (0.45) C5AR1KDM4EGAACASRDRD2
SCHEMBL649655 0.87 C5AR1 (0.47) C5AR1GAATP53SMN1; SMN2MEN1
SCHEMBL1912916 0.87 C5AR1 (0.47) C5AR1KDM4EGAACASRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed